Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Big Trial Update in ER+ Metastatic Breast Cancer!
Genentech just announced results from the Phase III persevERA trial evaluating giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- metastatic breast cancer.
The study did Not meet its primary endpoint of PFS, although a numerical improvement was observed and safety was consistent with known profiles.
So what does this mean? The oral SERD story remains complicated.
While persevERA missed its statistical endpoint in the endocrine-sensitive 1L setting, the broader giredestrant program is still moving forward:
- evERA (post-CDK setting) showed a meaningful PFS benefit with giredestrant + everolimus
- lidERA in early-stage disease showing early benefit but without cdk4/6
- pionERA will test giredestrant + CDK4/6 inhibitors in endocrine-resistant disease possible readout in 2027
- Awaiting SERENA04 (AZ)
Takeaway: Not every SERD + CDK4/6 combination will outperform AI + CDK4/6 in the frontline setting. But the field is clearly shifting toward next-generation ER degraders and precision endocrine therapy. Awaiting the full data to be presented.
The next few years will likely determine:
- where oral SERDs fit
- which biomarker-defined populations benefit most
- how they integrate with CDK4/6, PI3K/AKT inhibitors, and ADC sequencing
Breast oncology never stands still.”
Other articles about Matthew Kurian on OncoDaily.